Market closed
Keros Therapeutics/$KROS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Ticker
$KROS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
169
Website
KROS Metrics
BasicAdvanced
$455M
-
-$5.00
1.40
-
Price and volume
Market cap
$455M
Beta
1.4
52-week high
$69.26
52-week low
$9.78
Average daily volume
919K
Financial strength
Current ratio
21.453
Quick ratio
20.561
Long term debt to equity
2.954
Total debt to equity
3.3
Management effectiveness
Return on assets (TTM)
-26.73%
Return on equity (TTM)
-41.46%
Valuation
Price to revenue (TTM)
118.324
Price to book
0.8
Price to tangible book (TTM)
0.8
Price to free cash flow (TTM)
-2.58
Growth
Revenue change (TTM)
2,250.99%
Earnings per share change (TTM)
-3.68%
3-year revenue growth (CAGR)
-43.89%
3-year earnings per share growth (CAGR)
25.74%
What the Analysts think about KROS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Keros Therapeutics stock.
KROS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
KROS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
KROS News
AllArticlesVideos
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
GlobeNewsWire·3 weeks ago
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Keros Therapeutics stock?
Keros Therapeutics (KROS) has a market cap of $455M as of March 23, 2025.
What is the P/E ratio for Keros Therapeutics stock?
The price to earnings (P/E) ratio for Keros Therapeutics (KROS) stock is 0 as of March 23, 2025.
Does Keros Therapeutics stock pay dividends?
No, Keros Therapeutics (KROS) stock does not pay dividends to its shareholders as of March 23, 2025.
When is the next Keros Therapeutics dividend payment date?
Keros Therapeutics (KROS) stock does not pay dividends to its shareholders.
What is the beta indicator for Keros Therapeutics?
Keros Therapeutics (KROS) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.